Switch theme
Sign up to access all valuation multiples
Haisco Pharmaceutical Group Co Ltd is a pharmaceutical company based in China. It is mainly engaged in the research, development, manufacture, and sale of drugs for liver disease. Its product portfolio includes parenteral nutrition drugs, antibiotics, anesthetic agents, digestive system drugs and tumour adjuvant drug series. The company's products are being used in first rank hospitals in China.
2000
n/a
LTM Revenue $563M
LTM EBITDA $77.3M
$7.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Haisco Pharmaceutical has a last 12-month revenue of $563M and a last 12-month EBITDA of $77.3M.
In the most recent fiscal year, Haisco Pharmaceutical achieved revenue of $513M and an EBITDA of $103M.
Haisco Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Haisco Pharmaceutical valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $513M | $532M | XXX | XXX | XXX |
| Gross Profit | $289M | $328M | XXX | XXX | XXX |
| Gross Margin | 56% | 62% | XXX | XXX | XXX |
| EBITDA | $103M | $63.8M | XXX | XXX | XXX |
| EBITDA Margin | 20% | 12% | XXX | XXX | XXX |
| Net Profit | $38.2M | $40.7M | XXX | XXX | XXX |
| Net Margin | 7% | 8% | XXX | XXX | XXX |
| Net Debt | $141M | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Haisco Pharmaceutical's stock price is CNY 45 (or $6).
Haisco Pharmaceutical has current market cap of CNY 50.9B (or $7.0B), and EV of CNY 51.6B (or $7.1B).
See Haisco Pharmaceutical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $7.1B | $7.0B | XXX | XXX | XXX | XXX | $0.06 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Haisco Pharmaceutical has market cap of $7.0B and EV of $7.1B.
Haisco Pharmaceutical's trades at 12.6x LTM EV/Revenue multiple, and 91.9x LTM EBITDA.
Analysts estimate Haisco Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Haisco Pharmaceutical and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $7.1B | XXX | XXX | XXX |
| EV/Revenue | 13.4x | XXX | XXX | XXX |
| EV/EBITDA | 111.3x | XXX | XXX | XXX |
| P/E | 120.0x | XXX | XXX | XXX |
| P/E/Growth | 3.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpHaisco Pharmaceutical's NTM/LTM revenue growth is 21%
Haisco Pharmaceutical's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Haisco Pharmaceutical's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Haisco Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Haisco Pharmaceutical and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 4% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 12% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -38% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 33% | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 3% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 21% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 17% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 59% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Haisco Pharmaceutical acquired XXX companies to date.
Last acquisition by Haisco Pharmaceutical was XXXXXXXX, XXXXX XXXXX XXXXXX . Haisco Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Haisco Pharmaceutical founded? | Haisco Pharmaceutical was founded in 2000. |
| Where is Haisco Pharmaceutical headquartered? | Haisco Pharmaceutical is headquartered in China. |
| Is Haisco Pharmaceutical publicy listed? | Yes, Haisco Pharmaceutical is a public company listed on SHE. |
| What is the stock symbol of Haisco Pharmaceutical? | Haisco Pharmaceutical trades under 002653 ticker. |
| When did Haisco Pharmaceutical go public? | Haisco Pharmaceutical went public in 2012. |
| Who are competitors of Haisco Pharmaceutical? | Similar companies to Haisco Pharmaceutical include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Haisco Pharmaceutical? | Haisco Pharmaceutical's current market cap is $7.0B |
| What is the current revenue of Haisco Pharmaceutical? | Haisco Pharmaceutical's last 12-month revenue is $563M. |
| What is the current EBITDA of Haisco Pharmaceutical? | Haisco Pharmaceutical's last 12-month EBITDA is $77.3M. |
| What is the current EV/Revenue multiple of Haisco Pharmaceutical? | Current revenue multiple of Haisco Pharmaceutical is 12.6x. |
| What is the current EV/EBITDA multiple of Haisco Pharmaceutical? | Current EBITDA multiple of Haisco Pharmaceutical is 91.9x. |
| What is the current revenue growth of Haisco Pharmaceutical? | Haisco Pharmaceutical revenue growth between 2023 and 2024 was 4%. |
| Is Haisco Pharmaceutical profitable? | Yes, Haisco Pharmaceutical is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
